PUBLICATION
Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and their Zebrafish Homologs at the Blood-Brain Barrier
- Authors
- Quinlan, J.A., Sabbineni, S., Robey, R.W., Lipsey, C.C., Inglut, C.T., Thomas, J.R., Walker, J.R., Zhou, W., Huang, H.C., Gottesman, M.M.
- ID
- ZDB-PUB-240926-9
- Date
- 2024
- Source
- Molecular pharmacology 106(6): 278-286 (Journal)
- Registered Authors
- Keywords
- ABC transporters, blood-brain barrier, p-glycoprotein
- MeSH Terms
-
- ATP Binding Cassette Transporter, Subfamily B*/genetics
- ATP Binding Cassette Transporter, Subfamily B*/metabolism
- ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism
- ATP Binding Cassette Transporter, Subfamily G, Member 2*/genetics
- ATP Binding Cassette Transporter, Subfamily G, Member 2*/metabolism
- ATP-Binding Cassette Sub-Family B Member 4
- ATP-Binding Cassette Transporters/genetics
- ATP-Binding Cassette Transporters/metabolism
- Animals
- Animals, Genetically Modified*
- Biological Transport
- Blood-Brain Barrier*/metabolism
- HEK293 Cells
- Humans
- Neoplasm Proteins/genetics
- Neoplasm Proteins/metabolism
- Zebrafish*/metabolism
- Zebrafish Proteins*/genetics
- Zebrafish Proteins*/metabolism
- PubMed
- 39322411 Full text @ Mol. Pharmacol.
Citation
Quinlan, J.A., Sabbineni, S., Robey, R.W., Lipsey, C.C., Inglut, C.T., Thomas, J.R., Walker, J.R., Zhou, W., Huang, H.C., Gottesman, M.M. (2024) Identification of NanoLuciferase Substrates Transported by Human ABCB1 and ABCG2 and their Zebrafish Homologs at the Blood-Brain Barrier. Molecular pharmacology. 106(6):278-286.
Abstract
ATP-binding cassette (ABC) transporters expressed at the blood-brain barrier (BBB) impede delivery of therapeutic agents to the brain, including agents to treat neurodegenerative diseases and primary and metastatic brain cancers. Two transporters, P-glycoprotein (P-gp, ABCB1) and ABCG2, are highly expressed at the BBB and are responsible for the efflux of numerous clinically useful chemotherapeutic agents, including irinotecan, paclitaxel, and doxorubicin. Based on a previous mouse model, we have generated transgenic zebrafish where expression of NanoLuciferase (NanoLuc) is controlled by the promoter of glial fibrillary acidic protein, leading to expression in zebrafish glia. To identify agents that disrupt the BBB including inhibitors of ABCB1 and ABCG2, we identified NanoLuc substrates that are also transported by P-gp, ABCG2, and their zebrafish homologs. These substrates will elevate the amount of bioluminescent light produced in the transgenic zebrafish with BBB disrpution. We transfected HEK-293 cells with both NanoLuc and human ABCB1 or ABCG2, or their zebrafish homologs Abcb4 and Abcg2a, which are functionally homologous to human P-gp and ABCG2, respectively, and expressed at the zebrafish BBB. We evaluated the brightness of ten NanoLuc substrates, then screened the eight brightest for their ability to be effluxed by the ABC transporters. We identified one ABCB1 substrate, two Abcb4 substrates, six ABCG2 substrates, and four Abcg2a substrates. These data will aid in the development of a transgenic zebrafish model of the BBB to identify novel BBB disruptors and should prove useful in the development of other animal models that use NanoLuc as a reporter. Significance Statement The ATP-Binding Cassette (ABC) transporters ABCB1 and ABCG2 at the blood-brain barrier (BBB) hinder pharmacological treatment of brain-related diseases. Consequently, there is a need for tools to identify BBB disruptors. We conducted a screen of ten NanoLuciferase substrates, identifying the brightest and those that were transported by human and zebrafish ABC transporters at the BBB. This work supports and complements our development of a transgenic zebrafish model, in which NanoLuciferase is expressed within glial cells, enabling detection of BBB disruption.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping